Annual Securities Report — FY2025
What Immuno-Biological Laboratories Co.,Ltd. reported for the period from 2025-04-01 to 2026-03-31. Filed by 株式会社免疫生物研究所
Filed 2026-06-26View the original on EDINET
How much it says
61Detailed
What moved here
24named for the first time
Its own wording
70terms
Which filing this is
36/ 36newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
This filing presents the results and financial position for the consolidated fiscal year from 1 April 2025 to 31 March 2026, the Antibody-Related and Cosmetics-Related Businesses, research and development, capital expenditures and the governance structure. No major new event is apparent from the text; the filing primarily provides routine updates.
Komori's summary of this document, not the document's own words.61Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
80
Very detailed
68
Detailed
100
Very detailed
62
Detailed
0
Almost nothing
50
Typical
68
Detailed
37
Thin
60
Detailed
79
Very detailed
50
Typical
R&D spend1億円Money spent making new things.
Cash left over2億円Cash from the business, less what went into equipment.
Spent on equipment40百万円Plants, machines — things meant to last.
Employees60Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.